Journal of microbiology, epidemiology and immunobiologyJournal of microbiology, epidemiology and immunobiology0372-93112686-7613Central Research Institute for Epidemiology114610.36233/0372-9311-134UnknownCharacterization of virulent Escherichia coli strains isolated from patients with urological infectionSlukinP. V.<p>Pavel V. Slukin - researcher, Laboratoty of antimicrobial agents, Molecular microbiology department</p><p>Obolensk</p>xopgi@yandex.ruhttps://orcid.org/0000-0002-4976-0145AstashkinE. I.<p>Eugeny I. Astashkin - Cand. Sci. (Med.), leading researcher, Laboratoty of antimicrobial agents, Molecular microbiology department</p><p>Obolensk</p>fake@neicon.ruhttps://orcid.org/0000-0002-3559-9071AslanyanE. M.<p>Elena M. Aslanyan - researcher, Disinfectology department</p><p>Obolensk</p>fake@neicon.ruhttps://orcid.org/0000-0001-9538-9968ErshovaM. G.<p>Marina G. Ershova - Head, Microbiology laboratory</p><p>Yaroslavl</p>fake@neicon.ruhttps://orcid.org/0000-0003-4691-648XPoletaevaE. D.<p>Elena D. Poletaeva - bacteriologist, Microbiology laboratory</p><p>Yaroslavl</p>fake@neicon.ruhttps://orcid.org/0000-0002-7074-6989SvetochE. A.<p>Edward A. Svetoch - D. Sci. (Vet.), Professor, chief researcher, Laboratoty of antimicrobial agents, Molecular microbiology department</p><p>Obolensk</p>fake@neicon.ruhttps://orcid.org/0000-0002-3185-1954ShepelinA. P.<p>Anatoly P. Shepelin - D. Sci. (Biol.), Deputy director for scientific and industrial Work</p><p>Obolensk</p>fake@neicon.ruhttps://orcid.org/0000-0002-8253-7527FursovaN. K.<p>Nadezhda K. Fursova - Cand. Sci. (Biol.), leading researcher, Laboratoty of antimicrobial agents, Molecular microbiology department</p><p>Obolensk</p>fake@neicon.ruhttps://orcid.org/0000-0001-6053-2621State Research Center for Applied Microbiology and BiotechnologyInfectious Clinical Hospital No. 1100120229866716841001202210012022Copyright © 2022, Slukin P.V., Astashkin E.I., Aslanyan E.M., Ershova M.G., Poletaeva E.D., Svetoch E.A., Shepelin A.P., Fursova N.K.2022<p><strong>Objective</strong>. Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (UPEC) affect 150 million people annually.<br /><strong>Purpose</strong>: Characteristics of non-hospital strains of UPEC isolated from patients with UTI in Yaroslavl in 2016 2017.<br /><strong>Materials and methods</strong>. Susceptibility of UPEC strains (n = 20) to antibacterials was measured by the serial dilution method; the antibiotic resistance and virulence genes, phylogroups, O-serogroups and sequence types were identified by PCR and whole genome sequencing. The virulence of the strains was studied using the model of Galleria mellonella larvae.<br /><strong>Results</strong>. UPEC strains were classified as resistant (n = 11) and multi-drug resistant (n = 9) pathogens. Betalactamase genes bla<sub>TEM</sub> (n = 10), bla<sub>CTX</sub>-M (n = 6), class 1 integrons (n = 8), and gene cassettes dfrA17-aadA5 (n = 2), dfrA1 (n = 1) and aacA4-cmlA1 (n = 1) were identified. UPEC-virulence genetic determinants coding adhesins fimH, papG, sfaS, focG, afa/draBC, csgA, siderophores iroN, fyuA, iutA, counteracting factors of host immunity ompT, traT, toxins hlyA, cnf1, usp, capsule transporter kpsMTII, colicin cvaC, and pathogenicity islands I<sub>536</sub>, II<sub>536</sub>, III<sub>536</sub>, IV<sub>536</sub>, II<sub>J96</sub> и II<sub>CFT073</sub> were detected. Highly virulent and slightly virulent for G. mellonella larvae UPEC strains were obtained with LD<sub>50</sub> 10<sup>4</sup>10<sup>5</sup> and 10<sup>6</sup>10<sup>7</sup> CFU, respectively. The phylogroups A, B1, B2, E and F, serogroups О2, О4, О6, O9, O11, О15, О18, О25, О75 and O89, known sequence types ST14, ST58, ST69, ST73, ST93, ST127, ST131, ST-141, ST165, ST297, ST457, ST537, ST744, ST1434 and novel ST9239 and ST10102 were revealed.<br /><strong>Conclusions</strong>. The identified genetic diversity of non-hospital UPEC strains is consistent with the observed global trend in the spread of human pathogens, which are characterized with both high virulence and multiple drug resistance. This makes possible to assess prospectively the current epidemiological situation, give a forecast for its development in the future, as well as determine the optimal therapeutic options.</p>uropathogenic Escherichia colipathogenic factor genesmultilocus sequence typingwhole
genomе sequencingsequence-typeGalleria mellonellaUPECуропатогенные Escherichia coliгены факторов патогенностимультилокусное секвенирование-типированиеполногеномное секвенированиесиквенс-типыGalleria mellonella[1. Öztürk R., Murt A. Epidemiology of urological infections: a global burden. World J. Urol. 2020; 38: 2669–79. https://doi.org/10.1007/s00345-019-03071-4][2. Javed S., Mirani Z.A., Pirzada Z.A. Phylogenetic group B2 expressed significant biofilm formation among drug resistant uropathogenic Escherichia coli. Libyan. J. Med. 2021; 16(1): 1845444. https://doi.org/10.1080/19932820.2020.1845444][3. Палагин И.С., Сухорукова М.В., Дехнич А.В., Эйдельштейн М.В., Перепанова Т.С., Козлов Р.С. Антибиотикорезистентность возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового исследования «ДАРМИС-2018». Клиническая микробиология и антимикробная химиотерапия. 2019; 21(2): 134–46. https://doi.org/10.36488/cmac.2019.2.134-146][4. Medina M., Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther. Adv. Urol. 2019; 11: 1756287219832172. https://doi.org/10.1177/1756287219832172][5. Zhong Z.X., Cui Z.H., Li X.J., Tang T., Zheng Z.J., Ni W.N., et al. Nitrofurantoin combined with amikacin: a promising alternative strategy for combating MDR uropathogenic Escherichia coli.Front. Cell Infect. Microbiol. 2020; 10: 608547. https://doi.org/10.3389/fcimb.2020.608547][6. Naziri Z., Derakhshandeh A., Soltani Borchaloee A., Poormaleknia M., Azimzadeh N. Treatment failure in urinary tract infections: A warning witness for virulent multi-drug resistant ESBL-producing Escherichia coli. Infect. Drug Resist. 2020; 13: 1839–50. https://doi.org/10.2147/IDR.S256131][7. Sun D.H., Lv D.F., Mi Z.H., Hu L.Q., Huang Y., Gao X., et al. Investigation of antibiotic resistance determinants and virulence factors of uropathogenic Escherichia coli. J. Antibiot. (Tokyo). 2020; 73(5): 314–9. https://doi.org/10.1038/s41429-020-0284-7][8. Казанцев А.В., Осина Н.А., Глинская Т.О., Кошелева О.Н., Максимов Ю.В., Девдариани З.Л. и др. Факторы вирулентности и филогенетическая характеристика уропатогенных штаммов Eschericihia coli, выделенных на территории г. Саратова. Проблемы особо опасных инфекций. 2019; (4): 56–60. https://doi.org/10.21055/0370-1069-2019-4-56-60][9. Nüesch-Inderbinen M.T., Baschera M., Zurfluh K., Hächler H., Nüesch H, Stephan R. Clonal diversity, virulence potential and antimicrobial resistance of Escherichia coli causing community acquired urinary tract infection in Switzerland. Front. Microbiol. 2017; 8: 2334. https://doi.org/10.3389/fmicb.2017.02334][10. Noie Oskouie A., Hasani A., Ahangarzadeh Rezaee M., Soroush Bar Haghi M.H., Hasani A., Soltani E. A relationship between O-serotype, antibiotic susceptibility and biofilm formation in uropathogenic Escherichia coli. Microb. Drug. Resist. 2019; 25(6): 951–8. https://doi.org/10.1089/mdr.2018.0330][11. Baldiris-Avila R., Montes-Robledo A., Buelvas-Montes Y. Phylogenetic classification, biofilm-forming capacity, virulence factors, and antimicrobial resistance in uropathogenic Escherichia coli (UPEC). Curr. Microbiol. 2020; 77(11): 3361–70. https://doi.org/10.1007/s00284-020-02173-2][12. Кузнецова М.В., Проворова С.В., Кубарев О.Г., Юдин Д.П., Каримова Н.В., Баяндина Н.В. и др. Сравнительная характеристика штаммов уропатогенной Escherichia coli, выделенных в условиях поликлиники и стационара. Урология. 2018; (6): 37–44. https://doi.org/10.18565/urology.2018.6.37-44][13. Аминева Э.М., Бахарева Л.И. Характеристика Escherichia coli, выделенной из мочи пациентов при различных клинических ситуациях. Вестник Челябинского государственного университета. 2013; (7): 51–2.][14. Казанцев А.В. Определение принадлежности к О-серогруппе по результатам молекулярно-генетического анализа уропатогенных штаммов Escherichia coli, выделенных от пациентов, находящихся на госпитализации в урологических отделениях на территории г. Саратов, с симптомами пиелонефрита и цистита. В кн.: Материалы всероссийской научно-практической конференции с международным участием «Аспирантские чтения – 2018». Самара; 2018.][15. Alghoribi M.F., Gibreel T.M., Dodgson A.R., Beatson S.A., Upton M. Galleria mellonella infection model demonstrates high lethality of ST69 and ST127 uropathogenic E. coli. PLoS One. 2014; 9(7): e101547. https://doi.org/10.1371/journal.pone.0101547][16. Tsai C.J., Loh J.M., Proft T. Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing. Virulence. 2016; 7(3): 214–29. https://doi.org/10.1080/21505594.2015.1135289][17. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012; 18(3): 268–81. https://doi.org/10.1111/j.1469-0691.2011.03570.x][18. Кузина Е.С., Асташкин Е.И., Лев А.И., Агеева Е.Н., Карцев Н.Н., Светоч Э.А. и др. Интегроны классов 1 и 2 в госпитальных штаммах грам-отрицательных бактерий, выделенных в Москве и регионах Российской Федерации. Молекулярная генетика, микробиология и вирусология. 2019; 37(1): 17–24. https://doi.org/10.17116/molgen20193701117][19. Sabaté M., Moreno E., Pérez T., Andreu A., Prats G. Pathogenicity island markers in commensal and uropathogenic Escherichia coli isolates. Clin. Microbiol. Infect. 2006; 12(9): 880–6. https://doi.org/10.1111/j.1469-0691.2006.01461.x][20. Ашмарин И.П., Воробьев A.A. Статистические методы в микробиологических исследованиях. Ленинград: Наука; 1962.][21. Clermont O., Christenson J.K., Denamur E., Gordon D.M. The Clermont Escherichia coli phylo-typing method revisited: improvement of specificity and detection of new phylo-groups. Environ. Microbiol. Rep. 2013; 5(1): 58–65. https://doi.org/10.1111/1758-2229.12019][22. Iguchi A., Iyoda S., Seto K., Morita-Ishihara T., Scheutz F., Ohnishi M., et al. Escherichia coli O-genotyping PCR: a comprehensive and practical platform for molecular O serogrouping. J. Clin. Microbiol. 2015; 53(8): 2427–32. https://doi.org/10.1128/JCM.00321-15][23. Alikhan N.F., Zhou Z., Sergeant M.J., Achtman M. A genomic overview of the population structure of Salmonella. PLoS Genet. 2018; 14(4): e1007261. https://doi.org/10.1371/journal.pgen.1007261][24. Bankevich A., Nurk S., Antipov D., Gurevich A.A., Dvorkin M., Kulikov A.S., et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J. Comput. Biol. 2012; 19(5): 455–77. https://doi.org/10.1089/cmb.2012.0021][25. Angiuoli S.V., Gussman A., Klimke W., Cochrane G., Field D., Garrity G., et al. Toward an online repository of Standard Operating Procedures (SOPs) for (meta)genomic annotation. OMICS. 2008; 12(2): 137–41. https://doi.org/10.1089/omi.2008.0017][26. Edowik Y., Caspari T., Williams H.M. The amino acid changes T55A, A273P and R277C in the beta-lactamase CTX-M-14 render E. coli resistant to the antibiotic nitrofurantoin, a first-line treatment of urinary tract infections. Microorganisms. 2020; 8(12): 1983. https://doi.org/10.3390/microorganisms8121983][27. Kudinha T., Kong F., Johnson J.R., Andrew S.D., Anderson P., Gilbert G.L. Multiplex PCR-based reverse line blot assay for simultaneous detection of 22 virulence genes in uropathogenic Escherichia coli. Appl. Environ. Microbiol. 2012; 78(4): 1198–202. https://doi.org/10.1128/AEM.06921-11][28. Yu H., Qu F., Shan B., Huang B., Jia W., Chen C., et al. Detection of the mcr-1 colistin resistance gene in carbapenem-resistant Enterobacteriaceae from different hospitals in China. Antimicrob. Agents Chemother. 2016; 60(8): 5033–5. https://doi.org/10.1128/AAC.00440-16][29. Ageevets V., Lazareva I., Mrugova T., Gostev V., Lobzin Y., Sidorenko S. IncX4 plasmids harbouring mcr-1 genes: further dissemination. J. Glob. Antimicrob. Resist. 2019; 18: 166–7. https://doi.org/10.1016/j.jgar.2019.07.002]